In a previous work, we showed that low-dose celecoxib exerts antineoplastic effects in a melanoma co-culture treated with trametinib, by decreasing phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) resistance pathway activation [14]. The gene discussed is AKT1; the disease is melanoma.